AR125373A1 - ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONES - Google Patents
ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONESInfo
- Publication number
- AR125373A1 AR125373A1 ARP220100990A ARP220100990A AR125373A1 AR 125373 A1 AR125373 A1 AR 125373A1 AR P220100990 A ARP220100990 A AR P220100990A AR P220100990 A ARP220100990 A AR P220100990A AR 125373 A1 AR125373 A1 AR 125373A1
- Authority
- AR
- Argentina
- Prior art keywords
- variants
- equine
- plasma
- spike protein
- cov
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 3
- 241000283073 Equus caballus Species 0.000 abstract 7
- 229940096437 Protein S Drugs 0.000 abstract 5
- 101710198474 Spike protein Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 4
- 102000005593 Endopeptidases Human genes 0.000 abstract 3
- 108010059378 Endopeptidases Proteins 0.000 abstract 3
- 241000315672 SARS coronavirus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000000706 filtrate Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000001728 nano-filtration Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La presente divulgación divulga un proceso para obtener fragmentos de anticuerpos policlonales F(ab)₂ contra la proteína espicular o variantes de esta y del coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2) a partir de equinos hiperinmunizados. La presente divulgación también divulga un fragmento de anticuerpo policlonal F(ab)₂ contra la proteína espicular o variantes del SARS-CoV-2. También se divulga en el presente documento una composición que comprende los fragmentos de anticuerpos policlonales F(ab)₂. Los fragmentos de anticuerpos policlonales F(ab)₂ de la presente divulgación presentan una mejor actividad neutralizante contra diferentes variantes de RBD del SARS-CoV-2 y pueden utilizarse para el tratamiento de la enfermedad del coronavirus en un sujeto. Reivindicación 1: Un proceso para obtener fragmentos F(ab)₂ de anticuerpos policlonales contra la proteína espicular o las variantes de esta del síndrome respiratorio agudo grave coronavirus 2 caracterizado porque comprende: (a) obtener una formulación de antígenos que comprende la proteína espicular o variantes de esta del síndrome respiratorio agudo grave coronavirus 2 y al menos un adyuvante, donde la proteína espicular o las variantes de estas es al menos 200 residuos de aminoácidos contiguos de la SEQ ID Nº 1; (b) inmunizar un equino con la formulación de antígeno; (c) inmunizar el equino con uno o más dosis de refuerzo durante un periodo de tiempo en el intervalo de 21 a 30 días; (d) extraer sangre del equino después de 10 a 14 días posteriores a cada dosis de refuerzo y asilar el plasma de la sangre; (e) tratar el plasma con solución salina para obtener un plasma tratado; (f) digerir el plasma tratado del paso (e) con una endopeptidasa para obtener el plasma digerido con endopeptidasa; (g) precipitar el plasma digerido con la endopeptidasa del paso (f) con ácido octanoico para obtener una mezcla de antisuero de equino; (h) centrifugar y filtrar la mezcla de antisuero de equino mediante diafiltración; (i) purificar la mezcla de antisuero de equino mediante cromatografía para obtener un filtrado; y (j) purificar el filtrado del paso (i) mediante nanofiltración para obtener fragmentos F(ab)₂ de anticuerpos policlonales contra el coronavirus del síndrome respiratorio agudo grave de tipo 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121018115 | 2021-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125373A1 true AR125373A1 (es) | 2023-07-12 |
Family
ID=83722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100990A AR125373A1 (es) | 2021-04-19 | 2022-04-18 | ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONES |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR125373A1 (es) |
| WO (1) | WO2022224271A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2568838A1 (en) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| FR2899112B1 (fr) * | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament. |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10787501B1 (en) * | 2020-04-02 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
| CN112010963B (zh) * | 2020-07-20 | 2022-05-20 | 江苏集萃医学免疫技术研究所有限公司 | Sars-cov-2抗体及其用途 |
| KR102233689B1 (ko) * | 2020-11-26 | 2021-03-30 | 재단법인 오송첨단의료산업진흥재단 | SARS-CoV-2 스파이크 단백질의 수용체-결합 도메인에 특이적으로 결합하는 항체 및 이의 이용 |
-
2022
- 2022-04-18 AR ARP220100990A patent/AR125373A1/es unknown
- 2022-04-18 WO PCT/IN2022/050371 patent/WO2022224271A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022224271A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2633399C (en) | Therapeutic vaccine | |
| CO2021000326A2 (es) | Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas | |
| Brady | Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens | |
| ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
| US20170065702A1 (en) | Methods of modulating an immune response | |
| CO6640239A2 (es) | Proceso par preparar una composición de inmunoglobulina | |
| EP2500034A1 (en) | Therapeutic agent for psoriasis or atopic dermatitis | |
| JP2006347922A (ja) | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 | |
| AU2018341959B2 (en) | Anti-PACAP antibody | |
| AR078734A1 (es) | Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones | |
| US20180022790A1 (en) | Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases | |
| AR125373A1 (es) | ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONES | |
| TWI481411B (zh) | 登革疫苗、包含該登革疫苗之醫藥組合物、核苷酸序列、以及該醫藥組成物之製造方法 | |
| Squaiella-Baptistão et al. | Quality of horse F (ab′) 2 antitoxins and antirabies immunoglobulins: protein content and anticomplementary activity | |
| RU2020117362A (ru) | Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17) | |
| Shelke et al. | Equine rabies immunoglobulin: A review | |
| Lovreček et al. | A century of antivenom | |
| Kalil et al. | Production and utilization of snake antivenoms in South America | |
| BR112022014264A2 (pt) | Composições e métodos para aumentar ou melhorar a transdução de vetores de terapia genética e para remover ou reduzir imunoglobulinas | |
| CN1250572C (zh) | 能选择性检测朊病毒PrPsc同型异构体的抗体 | |
| Tizard | Passive immunization | |
| JPH06100591A (ja) | ペプチド、それらから誘導される抗体並びにその抗体を含有する抗ニュ−カッスル病薬 | |
| US606042A (en) | On-the-main | |
| RU2647374C1 (ru) | Способ профилактики анафилактического шока при введении гетерологических сывороток | |
| Di Martino et al. | Production and characterization of antibodies to mouse scrapie‐amyloid protein elicited by non‐carrier linked synthetic peptide immunogens |